Search

Displaying results 6171 - 6180 of 10000 in total
  1. Drug

    Interleukin-7

    go.drugbank.com/drugs/DB11997
    Investigational

    Interleukin 7 has been used in trials studying the treatment of Metastatic Breast Cancer.

    Synonyms: IL-7
  2. Drug

    rPSGL-Ig

    go.drugbank.com/drugs/DB06256
    Investigational

    Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc.

    Synonyms: rPSGL-Ig, rPSGL-1-Ig
  3. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

  4. Drug

    Lintitript

    go.drugbank.com/drugs/DB04867
    Experimental

    Lintitript is a new, highly specific and potent CCK-A receptor antagonist.

  5. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.

  6. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 is a marine derived compound. PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

  7. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  8. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Thus, the media in which they are cultured is believed to also have therapeutic potential. … Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.

  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  10. Drug

    Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16922
    Approved

    Inactivated viruses cannot replicate and thus cannot cause disease from infection, even in immunocompromised individuals. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen